AstraZeneca Plc stated on Tuesday it’s working with Oxford College to provide a vaccine for the Omicron coronavirus variant, becoming a member of different vaccine-makers who wish to develop the variant-specific vaccine.
“Along with Oxford College, we’ve got taken preliminary steps in producing an Omicron variant vaccine, in case it’s wanted and shall be knowledgeable by rising knowledge,” a spokesperson for the corporate stated in a press release.
Provinces take new measures to stem impression of Omicron variant
Oxford didn’t instantly reply to a request for remark outdoors enterprise hours.
Quebec breaks report for highest each day provincial COVID-19 case rely in Canada
What masks work finest in opposition to Omicron? Consultants are divided, however most say ditch material masks
The Monetary Occasions first reported the information, citing Sandy Douglas, a analysis group chief at Oxford.
“Adenovirus-based vaccines (resembling that made by Oxford/AstraZeneca) may in precept be used to answer any new variant extra quickly than some could beforehand have realized,” Douglas advised FT.
A lab-study final week discovered that AstraZeneca’s antibody cocktail Evusheld retained neutralizing exercise in opposition to the Omicron variant.
Vaccine makers Pfizer/BioNTech and Moderna additionally beforehand stated they had been engaged on Omicron- particular COVID-19 vaccines. Moderna stated hopes to begin scientific trials early subsequent 12 months.
View hyperlink »